Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EMN 2021 | CARTITUDE-1: promising initial results of cilta-cel for myeloma

Thomas Martin, MD, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, outlines initial results from the Phase Ib/II CARTITUDE-1 study (NCT03548207) investigating ciltacabtagene autoleucel (cilta-cel), a chimeric antigen receptor (CAR) T-cell therapy targeting B-cell maturation antigen (BCMA), in patients with relapsed/refractory multiple myeloma. The study reports an overall response rate of 96.9% with 67% of participants achieving a complete response. Of evaluable patients, 93% achieved measurable residual disease (MRD)-negativity. At a median follow-up of 12.4 months, the median progression-free survival had not been reached and the overall survival rate was 88.5%. Cilta-cel had a manageable safety profile at the recommended Phase II dose. This interview took place during the 2021 European Myeloma Network (EMN) congress.

Transcript (edited for clarity)

As everybody knows, the CARTITIDE-1 study was a study using a novel CAR T-cell therapy, targeting BCMA in relapsed and refractory myeloma. This was a heavily pre-treated population. They had three or more prior lines of therapy and they received this therapy independent of any maintenance-based therapy. They did get bridging chemotherapy that included cyclophosphamide and fludarabine. So cyclophosphamide, fludarabine, and then infusion of CAR-T cells and then we followed them for response as well as for quality of life afterwards...

As everybody knows, the CARTITIDE-1 study was a study using a novel CAR T-cell therapy, targeting BCMA in relapsed and refractory myeloma. This was a heavily pre-treated population. They had three or more prior lines of therapy and they received this therapy independent of any maintenance-based therapy. They did get bridging chemotherapy that included cyclophosphamide and fludarabine. So cyclophosphamide, fludarabine, and then infusion of CAR-T cells and then we followed them for response as well as for quality of life afterwards.

At ASH of this year, we presented, and it was presented by Deepu Madduri, an overall response rate of 97%, which is pretty amazing. And then a PFS that was still above 70% at 12 months post CAR T-cell therapy. So this therapy is likely going to have a PFS that is certainly longer than any other CAR T-cell therapy in multiple myeloma, and we’re all really anxiously awaiting the data to see what the actual PFS will be. But really a potent therapeutic for these patients, and again, these are very heavily pre-treated patients.

Read more...

Disclosures

Thomas Martin, MD, receives research funding to his institution from Sanofi, AMGEN, Janssen